175396-30-2

Basic information

• Product Name: Ethyl 7-oxo-4,5,6,7-tetrahydro-1h-indazole-3-carboxylate
• Synonyms: Ethyl 7-oxo-4,5,6,7-tetrahydro-1h-indazole-3-carboxylate
• CAS NO: 175396-30-2
• Molecular Formula: C₁₀H₁₂N₂O₃
• Molecular Weight: 208.21388
• Mol File: 175396-30-2.mol

Chemical Properties

• Boiling Point: 451.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.311±0.06 g/cm3(Predicted)
• PKA: 8.84±0.20(Predicted)
• CAS DataBase Reference: Ethyl 7-oxo-4,5,6,7-tetrahydro-1h-indazole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 7-oxo-4,5,6,7-tetrahydro-1h-indazole-3-carboxylate(175396-30-2)
• EPA Substance Registry System: Ethyl 7-oxo-4,5,6,7-tetrahydro-1h-indazole-3-carboxylate(175396-30-2)

Safety Data

• Hazardous Substances Data: 175396-30-2(Hazardous Substances Data)

Upstream product

• 95-92-1 oxalic acid diethyl ester 
• 802541-12-4 ethyl (3-ethoxy-2-oxocyclohex-3-en-1-yl)-(oxo)acetate 

Downstream Products

• 1382036-85-2 ethyl 1-(4-methoxybenzyl)-7-oxo-4,5 ,6,7-tetrahydro-1H-indazole-3-carboxylate 
• 1382036-86-3 ethyl 2-(4-methoxybenzyl)-7-oxo-4,5,6,7-tetrahydro-2H-indazole-3-carboxylate 

Relevant articles and documents

SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to substituted pyrazolo[4,3-/h]quinazoline compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular PIM kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

Identification of 4,5-dihydro-1 H -pyrazolo[4,3- h ]quinazoline Derivatives as a new class of orally and selective polo-like kinase 1 inhibitors

Polo-like kinase 1 (Plk1) is a fundamental regulator of mitotic progression whose overexpression is often associated with oncogenesis and therefore is recognized as an attractive therapeutic target in the treatment of proliferative diseases. Here we discuss the Structure-activity relationship of the 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline class of compounds that emerged from a high throughput screening (HTS) campaign as potent inhibitors of Plk1 kinase. Furthermore, we describe the discovery of 49, 8-{[2-methoxy-5-(4- methylpiperazin-1-yl)phenyl]amino}-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline-3-carboxamide, as a highly potent and specific ATP mimetic inhibitor of Plk1 (IC50 = 0.007 μM) as well as its crystal structure in complex with the methylated Plk136-345 construct. Compound 49 was active in cell proliferation against different tumor cell lines with IC 50 values in the submicromolar range and active in vivo in the HCT116 xenograft model where it showed 82% tumor growth inhibition after repeated oral administration.

SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

Pyrazolo-quinazoline derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may

PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.